

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 November 2000 (30.11.2000)

PCT

(10) International Publication Number  
**WO 00/70964 A1**

- (51) International Patent Classification<sup>7</sup>: A23L 1/054, 1/308, 1/30 (74) Agent: LOCK, Graham; 55, Avenue Nestlé, CH-1800 Vevey (CH).
- (21) International Application Number: PCT/EP00/04744 (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 19 May 2000 (19.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 99109916.9 20 May 1999 (20.05.1999) EP (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): SOCI-ETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box 353, CH-1800 Vevey (CH).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): JANN, Alfred [CH/FR]; 255, rte de Pays de Gavot, F-74500 Publier (FR). ARRIGONI, Eva [CH/CH]; Mühlebachstr. 26, CH-8800 Thalwil (CH). ROCHAT, Florence [CH/CH]; Quartier des Tilleuls 6, CH-1820 Montreux (CH). SCHMID, Daniel [CH/CH]; 6, rue Orient-Ville, CH-1005 Lausanne (CH). BAUCHE, Anne [FR/CH]; Av. de la Sallaz 50, CH-1010 Lausanne (CH).
- Published:**  
— With international search report.  
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 00/70964 A1

(54) Title: METHOD FOR INCREASING PROPIONATE IN THE GASTRO-INTESTINAL TRACT

(57) Abstract: A method for selectively increasing the production of propionate in the gastro-intestinal tract of a mammal. The method includes the step of enterally administering to the mammal a nutritional composition which contains dextran. Increasing the propionate production results in decreased blood cholesterol levels, decreased blood triglyceride levels, decreased very low density lipoprotein levels, increased high density lipoprotein levels, and increased insulin sensitivity.

WO 00/70964

PCT/EP00/04744

**Method for Increasing Propionate  
in the Gastro-Intestinal Tract**

### Summary of the invention

Accordingly, in one aspect, this invention provides a method for selectively increasing the production of propionate in the gastro-intestinal tract, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

It has been surprisingly found that dextran, when fermented by micro-organisms which occur in the gastro-intestinal tract, results in the increased production of propionate when compared to other non-digestible polysaccharides. Therefore, dextran is an ideal source of propionate in the gastro-intestinal tract.

The term "dextran" means a group of polysaccharide which are composed of  $\alpha$ -D-glucopyranosyl units linked predominantly  $\alpha$ -D(1 $\rightarrow$ 6). Dextrans are produced by certain types bacteria growing on a glucose substrate; for example *Leuconostoc mesenteroides*, *Leuconostoc dextranicum*, and *Leuconostoc mesenteroides ssp. cremoris*. Further, shorter chain dextrans may be obtained by hydrolysing native dextrans or by synthesising them.

In another aspect, this invention provides a method for decreasing blood cholesterol levels in a mammal, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

In another aspect, this invention provides a method for decreasing blood triglyceride levels in a mammal, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

In another aspect, this invention provides a method for decreasing very low density lipoprotein levels in a mammal, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

In another aspect, this invention provides a method for increasing high density lipoprotein levels in a mammal, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

In another aspect, this invention provides a method for increasing insulin sensitivity in a mammal, the method comprising enterally administering to a mammal a nutritional composition which contains dextran.

### Detailed Description of the Preferred Embodiments

Embodiments of the invention are now described, by way of example only.

This invention is based upon the discovery that the colonic fermentation of dextran by micro-organisms results in the production of relatively larger amounts of propionate as compared to other non-digestible polysaccharides. Therefore, the enteral administration of dextran provides a convenient and simple way of  
5 selectively increasing the production of propionate in the gastro-intestinal tract.

The dextran used may be any suitable dextran; natural, synthetic or partially hydrolysed. Suitable dextrans are commercially available or may be produced by growing *Leuconostoc* micro-organisms on a sucrose substrate and isolating and purifying the dextran. Alternatively, the dextran may be produced as described  
10 in European patent application 0881283.

Preferably, however, the dextran is a high molecular weight dextran; for example having a molecular weight above 50000, preferably above about 70000, more preferably above about 100000; for example above about 500000.

The dextran may be formulated into any suitable nutritional composition as  
15 desired since the exact composition and form is not critical. One suitable class of nutritional compositions is food products. Examples of suitable food products include yoghurts, ice cream confections, milk-based drinks, salad dressings, sauces, toppings, desserts, confectionery products, biscuits, cereal-based snack bars, prepared dishes, and the like. For humans, food products which are  
20 convenience foods are preferred since patient compliance is increased. Another suitable class of nutritional compositions is nutritional formulas such as enteral formulas for clinical and infant nutrition, and nutritional supplements. For pets, the nutritional compositions may be in the form of pet foods such as dried kibbles and retorted wet products.

25 The nutritional compositions may contain other ingredients as desired. For example, the nutritional compositions may contain other polysaccharides such as insoluble and soluble fibres. Fibres are known to have a beneficial effect upon cholesterol and glucose levels. Suitable sources of soluble and insoluble fibres are commercially available.

30 An example of a suitable fibre is inulin or its hydrolysis products. The inulin may be provided in the form of a natural extract which is suitable for human consumption. Suitable inulin extracts may be obtained from Orafit SA of Tirlemont 3300, Belgium under the trade mark "Raftiline". For example, the inulin may be provided in the form of Raftiline®ST which is a fine white powder  
35 which contains about 90 to about 94% by weight of inulin, up to about 4% by weight of glucose and fructose, and about 4 to 9% by weight of sucrose. The

average degree of polymerisation of the inulin is about 10 to about 12. The hydrolysis products of inulin are fructo-oligosaccharides in the form of fructose oligomers containing 1-kestose(GF2), nystose(GF3), and 1F-fructofuranosyl nystose(GF4), in which fructosyl units(F) are bound at the  $\beta$ -2,1 position of sucrose(GF) respectively. The fructo-oligosaccharides may be obtained commercially, for example from Orafit SA of Tirlemont 3300, Belgium under the trade mark "Raftilose", or from Meiji Seika Co. of Japan. For example, the fructo-oligosaccharides may be provided in the form of Raftilose®P95. Other oligosaccharides may be included if desired. Suitable examples are galacto-oligosaccharides, xylo-oligosaccharides or oligo derivatives of starch.

If both soluble and insoluble fibre are used, the ratio of soluble fibre to insoluble fibre is preferably about 1:3 to about 3:1; more preferably about 1:1 to about 2:1.

The nutritional composition may also contain vitamins and minerals as desired. For clinical applications, the nutritional composition preferably includes a complete vitamin and mineral profile. For example, sufficient vitamins and minerals may be provided to supply about 25% to about 250% of the recommended daily allowance of the vitamins and minerals per 1000 calories of the nutritional composition.

When the nutritional composition is in the form of a food product or nutritional formula, the nutritional composition may contain a protein source, a lipid source and a carbohydrate source. These sources may be selected as desired.

The lipid source is preferably rich in monounsaturated fatty acids; for example monounsaturated fatty acids may provide at least 50% of energy of the lipid source. The lipid source may also contain polyunsaturated fatty acids (omega-3 and omega-6 fatty acids). The lipid profile is preferably designed to have a polyunsaturated fatty acid omega-6 (n-6) to omega-3 (n-3) ratio of about 4:1 to about 10:1. Saturated fatty acids preferably provide less than 20% of the energy of the lipid source; for example less than about 15%.

The nutritional composition may be used in the nutritional management of conditions such as diabetes and hypercholesterolemia.

The amount of the nutritional composition required to be fed to a patient will vary depending upon factors such as the patient's condition, the patient's body weight, the age of the patient, and whether the nutritional composition is the sole source of nutrition. However the required amount may be readily set by

a medical practitioner. In general, sufficient of the nutritional composition is administered to provide the patient with up to about 40 g of dietary fibre (insoluble and soluble) per day; for example about 25 g to about 35 g of dietary fibre per day. The amount of dextran that the patient receives is preferably in the  
5 range of about 2g to about 15g per day. If the nutritional formula is used as a supplement to other foods, the amount of the nutritional composition that is administered daily may be decreased accordingly.

The nutritional composition may be taken in multiple doses, for example 2 to 5 times, to make up the required daily amount or may taken in a single dose.  
10 The nutritional composition may also be fed continuously over a desired period.

The invention is now further described with reference to the following specific examples.

15 Example 1

Three non-digestible polysaccharides are fermented in an *in vitro* fermentation model which simulates fermentation conditions in the gastro-intestinal tract. The polysaccharides are (i) acacia gum (available under the trade  
20 name Fibregum), (ii) Dextran produced according to European patent application 0881283, and (iii) lactulose.

For each polysaccharide, an amount of 100 mg of the polysaccharide is added to 8 ml of a carbonate-phosphate buffer, which contains oligo-elements, in a 50 ml air-tight flask. The composition of the buffer is as follows:-

Component	Amount
NaHCO <sub>3</sub>	9.240g/l
Na <sub>2</sub> HPO <sub>4</sub> · 12H <sub>2</sub> O	7.125g/l
NaCl	0.470g/l
KCl	0.450g/l
Urea	0.400g/l
CaCl <sub>2</sub> · 6H <sub>2</sub> O	0.108g/l
Na <sub>2</sub> SO <sub>4</sub>	0.100g/l
MgCl <sub>2</sub> · 6H <sub>2</sub> O	0.100g/l
FeSO <sub>4</sub> · 7H <sub>2</sub> O	36.80mg/l
MnSO <sub>4</sub> · H <sub>2</sub> O	11.59mg/l
ZnSO <sub>4</sub> · 7H <sub>2</sub> O	4.40mg/l
CoCl <sub>2</sub> · 6H <sub>2</sub> O	1.20mg/l
NiCl <sub>2</sub>	1.00mg/l
CuSO <sub>4</sub> · 5H <sub>2</sub> O	0.98mg/l
Mo <sub>7</sub> (NH <sub>4</sub> ) <sub>6</sub> O <sub>24</sub> · 4H <sub>2</sub> O	0.17mg/l
Resazurine	1.00mg/l

Each flask is rinsed for 1 minute with CO<sub>2</sub> gas and stored at 4°C for 16 hours under a slight over-pressure.

- 5 Dilute human faeces is prepared from samples of fresh faeces collected from healthy humans not having consumed antibiotics for at least 3 months and not producing methane. The faeces are immediately rinsed with CO<sub>2</sub> gas, and 3 parts (weight/weight) of the carbonate-phosphate buffer with oligo-elements are rapidly added at 37°C. The mixture is blended for 2 minutes in a stomacher
- 10 (Stomacher 400, Seward, London, GB) and filtered by a Polymon PES1000/45 filter with 1 mm holes (Schweizerische Seidenfabrik SA, Zürich, CH).

- An amount of 2 ml of the dilute faeces is added to each flask and the head space gas is replaced by a flux of temperate CO<sub>2</sub> gas for 1 minute. After equilibration of the pressure, each flask is sealed air-tight and incubated in an
- 15 agitated water bath at 37°C.

After 24 hours, the content of short chain fatty acids in the flasks determined twice by direct injection of an acidified and sterile filtered sample on a gas chromatograph with FID (HP 8960, Hewlett Packard, Urdorf, CH) fitted

with a DB-FFAP capillary column (MSP FRIEDLI & Co, Koeniz, CH). The results are as follows:-

Polysaccharide	Short Chain fatty acid	SCFA Content ( $\mu\text{mol}/100\text{mg}$ )	SCFA % of total*
Fibregum	Acetate	648.2	63.7
	Propionate	228.6	22.5
	Butyrate	107.1	10.5
Dextran	Acetate	415.0	46.3
	Propionate	363.5	40.6
	Butyrate	87.6	9.8
Lactulose	Acetate	909.2	74.6
	Propionate	111.7	9.2
	Butyrate	172.2	14.1

5           \* the percentages do not added up to 100% since other short chain fatty acids are present in minor amounts.

10           The results indicate that fermentation of dextran results in increased production of propionate; relatively and absolutely. For the other polysaccharides, only acetate was favoured.

### Example 2

15           A study is undertaken with 45 mice aged between 7 and 10 weeks. The mice are kept in sterile conditions in cages. The mice have free access to water and a standard diet.

20           On the first day of the study, each mouse is fed 0.5 ml of a complete human microbial flora, diluted 100 times, by intra-gastric tube. The feeding is repeated on day 2. On day 11, the mice are separated into three groups; each group being housed in a separate sterile isolation unit.

          On day 15, each group of mice receives a test diet. The test diets are sterile. The test diets all contain a potato puree, sugar, fish meal, cellulose, vitamins and minerals and a non-digestible polysaccharide. The polysaccharides are as follows:-



Diet	Polysaccharide
Positive Control	Fructo-oligosaccharide (Raftilose)
Negative Control	Cellulose
Diet 1	Dextran

The mice are fed the diets until day 36. During this time, the development of the intestinal flora of each mouse is monitored by collecting faeces and determining microbial counts. A blood sample is collected from each mouse and analysed for short chain fatty acids. The mice are then anaesthetised and sacrificed. The caecum and stomach contents of each mouse is removed and analysed for short chain fatty acids and microbial flora, respectively.

All mice fed Diet 1 have relatively higher levels of propionate in the blood and caecum.

### Example 3

A study was performed to evaluate with 3 to 5 volunteers whether a significant increase of propionic acid could be measured in feces after consumption of an acute dose of 15g Dextran T2000 and a chronic dose of 10g Dextran T2000 per day.

This study was performed as a randomized placebo-controlled double blind study with 4 volunteers in a cross-over design. SCFAs were measured in feces. Additionally, blood formula and selected blood proteins were measured before and after consumption of the dextran.

#### Outline of Results

- a) the effect of an acute dose of 15g dextran on propionic acid in feces was investigated. The pool of feces collected between 12 and 72 hours after consumption of the acute dose was analysed for short chain fatty acids (SCFAs). Taking the average results of the 4 volunteers, propionic acid in feces of the pool increased by 3.43 mmol in the treatment group relative to the placebo group.
- b) a chronic consumption of 10g dextran per day was investigated. Propionic acid concentration in a fecal sample was analysed after 1 week of chronic consumption. Taking the average of the 4 volunteers, propionic acid concentration increased by 24.0  $\mu\text{mol/g}$  dry feces in the treatment group compared to a decrease of 5.7  $\mu\text{mol/g}$  dry feces in the placebo group.

Consumption of dextran induced no relevant changes of blood formula, investigated blood proteins or blood plasma enzymes. No clinical symptoms have been reported.

#### Conclusions

- 5       The results indicate an increase in the level of propionic acid in the gastrointestinal tract following consumption of dextran.

#### Results

- 10       A summary of results from the study on dextran is set out below. This was a placebo controlled double blind study with a cross-over design. 4 volunteers were enrolled.

- 15       Results are given separately for treatment (Dextran) and placebo (maltodextrin). Additionally results relative to placebo are given.

## fecal samples (1 week intake of 10g per day)

Treatment		C2: acetic acid		C3: propionic acid		In average:
volunteer	pionate conc.	C3/C2	% propionic acid			
1	89.89	-0.139	0.1			During treatment, propionate concentration increased by 24.0 $\mu\text{mol/g}$ dry feces. During treatment, propionate/acetate ratio decreased by 0.04. During treatment, %age of propionate on total SCFAs increased by 1.9%.
2	-13.73	-0.087	-2.7			
3	1.31	0.071	6.8			
4	18.43	0.007	3.3			
av	23.98 $\mu\text{mol/g dry}$	-0.037	1.9			
Placebo		C3/C2		% propionic acid		
volunteer	pionate conc.	C3/C2	% propionic acid			
1	11.39	-0.027	-0.7			During placebo, propionate concentration decreased by 5.7 $\mu\text{mol/g}$ dry feces. During placebo, propionate/acetate ratio decreased by 0.05. During placebo, %age of propionate on total SCFAs decreased by 1.6%.
2	-2.35	-0.144	-4.6			
3	-27.51	-0.041	-0.9			
4	-4.36	-0.002	-0.2			
av	-5.71 $\mu\text{mol/g dry}$	-0.054	-1.6			
treatm - plac.		C3/C2		% propionic acid		
volunteer		C3/C2	% propionic acid			
1	78.50	-0.112	0.8			Relative to placebo, propionate concentration increased by 29.7 $\mu\text{mol/gdry}$ feces. Relative to placebo, propionate/acetate ration increased by 0.02. Relative to placebo, %age of propionate on total SCFAs increased by 3.5%.
2	-11.38	0.057	1.9			
3	28.82	0.112	7.7			
4	22.79	0.009	3.5			
av	29.68 $\mu\text{mol/g dr}$	0.02	3.5			

pool of feces (12h to 72h after intake of 15g)					In blood, no changes in SCFA concentrations were observed.	
treatment		C3 produce C3 in tot			In average:	
		C3/C2	conc. C3 ( $\mu\text{mol/g wet}$ )			
1	29.65	30.32	0.57	35.54		
2	2.26	20.98	0.39	8.61		During treatment, propionate production was 10.8 mmol.
3	8.41	22.31	0.47	35.86		During treatment, %age of propionate on total SCFAs was 23%.
4	2.91	18.20	0.34	13.88		During treatment, propionate by acetate ratio 0.44.
av	10.81	22.95	0.44	23.47		During treatment, propionate concentration was 23.5 $\mu\text{mol/g wet feces}$ .
placebo						
		C3 produce C3 in tot			C3/C2 conc. C3 ( $\mu\text{mol/g wet}$ )	
		C3/C2	conc. C3 ( $\mu\text{mol/g wet}$ )			
1	17.11	24.84	0.44	26.84		
2	3.91	18.13	0.35	11.97		During treatment, propionate production was 7.4 mmol.
3	4.46	22.37	0.48	22.96		During treatment, %age of propionate on total SCFAs was 20.4%.
4	4.04	16.39	0.27	10.35		During treatment, propionate by acetate ratio 0.39.
av	7.38	20.43	0.39	18.03		During treatment, propionate concentration was 18.0 $\mu\text{mol/g wet feces}$ .
treatment - placebo						
		C3 produce C3 in tot			C3/C2 conc. C3 ( $\mu\text{mol/g wet}$ )	
		C3/C2	conc. C3 ( $\mu\text{mol/g wet}$ )			
1	12.54	5.48	0.13	8.69		Relative to placebo, propionate production increased by 3.4 mmol.
2	-1.65	2.84	0.04	-3.37		Relative to placebo, %age of propionate on total SCFAs increased by 2.5%.
3	3.95	-0.06	-0.01	12.90		Relative to placebo, propionate/acetate ratio increased by 0.06 (or 15%).
4	-1.12	1.81	0.06	3.53		Relative to placebo, propionate concentration increased by 5.4 $\mu\text{mol/g wet feces}$ .
av	3.43	2.52	0.06	5.44	(=+15%)	

Claims

1. The use of dextran in the preparation of a nutritional composition for selectively increasing the production of propionate in the gastro-intestinal tract of a mammal.  
5
2. The use of dextran in the preparation of a nutritional composition for decreasing blood cholesterol levels in a mammal.
- 10 3. The use of dextran in the preparation of a nutritional composition for decreasing blood triglyceride levels in a mammal.
4. The use of dextran in the preparation of a nutritional composition for decreasing very low density lipoprotein levels in a mammal.  
15
5. The use of dextran in the preparation of a nutritional composition for increasing high density lipoprotein levels in a mammal.
6. The use of dextran in the preparation of a nutritional composition for increasing insulin sensitivity in a mammal.  
20
7. The use according to any of claims 1 to 6 in which the dextran is a high molecular weight dextran having a molecular weight above about 500000.
- 25 8. The use according to any of claims 1 to 7 in which the nutritional composition further comprises inulin, fructo-oligo saccharide, galacto-oligosaccharides, or xylo-oligosaccharides, or mixtures thereof.
9. The use according to any of claims 1 to 8 in which the nutritional composition further comprises a lipid source which is rich in monounsaturated fatty acids and poor in saturated fatty acids.  
30

# INTERNATIONAL SEARCH REPORT

In **ational Application No**  
**PCT/EP 00/04744**

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23L1/054 A23L1/308 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, FSTA, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 382 355 A (HAYASHIBARA) 16 August 1990 (1990-08-16) page 1, line 10-25 page 2, line 32-35 page 9, line 10-13 page 9, line 16-19	1-9
Y	claims 1,2,6,7,9,12,13	1-5
X	EP 0 153 013 A (FISONS) 28 August 1985 (1985-08-28) page 2, line 15-19 page 3, line 20 -page 4, line 12 page 4, line 10-17 page 5, line 7-10 page 6, line 23-25 page 7, line 18,19 claims 1-9	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 October 2000

Date of mailing of the international search report

25/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tallgren, A

# INTERNATIONAL SEARCH REPORT

In .ational Application No

PCT/EP 00/04744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PATENT ABSTRACTS OF JAPAN vol. 010, no. 043 (C-329), 20 February 1986 (1986-02-20) & JP 60 190717 A (MEITOU SANGYO KK), 28 September 1985 (1985-09-28) abstract	1-5
A	--- D.SOUTHGATE ET AL.: "Dietary Fibre:Chemical and biological Aspects" 1990 , ROYAL SOCIETY OF CHEMISTR , CAMBRIDGE,GB XP002122986 pages 340-343 page 340, paragraph 3 page 341, paragraph 2 page 343, line 16-26	1-9
A	--- D.MC CORMICK ET AL: "Annual Review of Nutrition" , ANNUAL REVIEWS , PALO ALTO,CALIFORNIA,USA XP002123057 cited in the application pages 117-143 page 123, paragraph 2 page 126, paragraph 1 page 129, paragraph 3 -page 130, paragraph 1 page 131, paragraph 3 - paragraph 4	1-8
A	--- EP 0 881 283 A (NESTLE) 2 December 1998 (1998-12-02) cited in the application claims -----	1-9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In. tional Application No

PCT/EP 00/04744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 382355 A	16-08-1990	JP 2289520 A JP 2779963 B CA 2007270 A DE 69031285 D DE 69031285 T	29-11-1990 23-07-1998 09-08-1990 25-09-1997 12-02-1998
EP 153013 A	28-08-1985	AT 56148 T AU 571641 B AU 3819385 A DE 3579471 D DK 39685 A JP 60188403 A	15-09-1990 21-04-1988 08-08-1985 11-10-1990 02-08-1985 25-09-1985
JP 60190717 A	28-09-1985	JP 1797796 C JP 5002652 B	28-10-1993 13-01-1993
EP 881283 A	02-12-1998	AU 6901598 A BR 9801736 A CA 2233411 A CN 1201039 A CZ 9801669 A HU 9801263 A JP 11009266 A NO 982004 A NZ 330239 A PL 326483 A US 6004800 A	03-12-1998 11-01-2000 30-11-1998 09-12-1998 13-01-1999 28-07-1999 19-01-1999 01-12-1998 28-01-1999 07-12-1998 21-12-1999